BioRay Pharm is a biopharmaceutical company that specializes in the research, development, and commercialization of innovative therapeutic products. The company focuses on the discovery of new drugs and the improvement of existing therapies to address unmet medical needs, primarily in the field of oncology.

BioRay Pharm

BioRay is a commercial-stage biopharmaceutical company with a full suite of end-to-end capabilities in China. We focus on discovering, developing, manufacturing and commercializing medicines for immune-mediated diseases. Leveraging our expertise in immunology and diverse portfolio covering different therapeutic targets and cellular pathways, we are committed to delivering life-changing medicines and other treatment solutions for patients living with autoimmune diseases and cancer. BioRay has full-spectrum R&D expertise from drug discovery to late-stage development, industry-leading commercial-scale manufacturing and quality management systems, and a robust pipeline with more than 20 preclinical candidates and over 10 ongoing clinical projects. In addition, our well-established nationwide commercial operations support four marketed products in mainland China. Currently, we operate four R&D and manufacturing centers in Taizhou, Hangzhou and Shanghai, China and San Diego, US, and have over 1,300 employees worldwide dedicated to building a pre-eminent biopharmaceutical company by offering medicines of the highest quality while pushing the boundaries of scientific discovery. 

For more information about BioRay, please visit the company website: www.bioraypharm.com

BioRay Pharmaceutical

Stop by our posters for BioRay's innovative ADC pipelines at the AACR 2024 🚀 Particularly for the debut of our dual-payload ADC 😀   Gang Chen, Zhenwu Luo, Xiaobei Zhao Jie Zhu 

📆 Monday Apr 8, 2024 9:00 AM - 12:30 PM: 
🏆 BRY812, an anti-LIV-1 ADC with novel conjugation method for cancer therapeutics, Poster Section 22, Poster Board Number 30, Abstract 1886
🏆  Developing a biparatopic anti-ROR1 ADC for hematological and solid tumor treatment, Poster Section 22, Poster Board Number 29, Abstract 1885

📆Monday Apr 8, 2024 1:30 PM - 5:00 PM
🏆 BR113, a novel dual drug ADC has synergetic anti-tumor activity in solid tumor models, Poster Section 21, Poster Board Number 13, Abstract 1885

#ADC #LIV1 #ROR1 #ACCR #dualpayload #iADC

Last week, Anruixi® (Zuberitamab), our newly launched innovative mAb for treating NHL, has successfully entered national reimbursement list! More progress for immunology indications to be announced in 2024!

Our Anjianning® (biosimilar adalimumab) is now available to patients in Pakistan - great joint effort with our partner The SEARLE Company Ltd.

💡🌏 Asia-Pacific is now establishing itself as a global innovation hub, with China, Japan, and Korea leading the space in overall innovative pipeline assets in the region.

💊There has also recently been a shift in the region from predominantly producing generics to developing innovative technologies, and, in the last 10 years, the region has become a particular hotspot for clinical trials, contributing almost 50% of new clinical trial activity globally, according to Cytel.

🚀 Furthermore, Asia-Pacific’s pharmaceutical market is forecast to record 4.2% growth from 2022 to 2027, with China and Japan expected to dominate the market in terms of value.

And, with the rise of its biopharma industry, Asia-Pacific now has several biotech hubs that are home to companies that are helping to drive innovation in the region.

So, to find out more about some of these companies, read our latest article! 👇️

https://loom.ly/aqJGgt0

#AsiaPacific #innovation #InnovativeTechnologies #generics #BiotechHubs

Acepodia | Albatroz Therapeutics |  Aravax | Atom Bioscience | Cyrus Therapeutics | BioRay Pharmaceutical | Heartseed Inc.  | Immuneel Therapeutics Pvt. Ltd. | Neurophth Therapeutics / 纽福斯生物科技有限公司 | 百明信康生物技术（杭州）有限公司 Worgpharma 


COM:BIORAYPHARM

BioRay Pharm

Financials Not Available